LGN Legence Corp.
Research report · from SEC EDGAR · close 2026-07-13
executive summary
Legence Corp. (LGN). Revenue is $2.55B (+21.5% y/y) at a -2% net margin. It is not yet profitable. Our health score is B (74/100). No major red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$2.55B
+21.5% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 2
Cash & ST investments
$244.6M
Operating cash flow
$256.9M
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.